BAXBAXTER INTERNATIONAL INC

NYSE baxter.com


$ 35.29 $ -0.14 (-0.4 %)    

Monday, 22-Jul-2024 14:22:02 EDT
QQQ $ 483.09 $ 2.67 (0.56 %)
DIA $ 403.66 $ -0.37 (-0.09 %)
SPY $ 554.84 $ 2.62 (0.47 %)
TLT $ 92.60 $ -0.80 (-0.86 %)
GLD $ 221.40 $ 0.00 (-0 %)
$ 35.35
$ 35.44
$ 0.00 x 0
$ 35.31 x 112
$ 34.97 - $ 35.49
$ 30.28 - $ 48.69
4,497,448
na
18.03B
$ 0.62
$ 6.81
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-08-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-09-2023 12-31-2022 10-K
7 10-27-2022 09-30-2022 10-Q
8 07-28-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-28-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-11-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 03-17-2020 09-30-2019 10-Q
19 03-17-2020 12-31-2019 10-K
20 07-30-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-21-2019 12-31-2018 10-K
23 11-05-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-23-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-06-2015 03-31-2015 10-Q
38 02-26-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-30-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baxter-international-says-some-operations-being-resumed-on-manual-basis-until-full-restoration-is-possible

- Reuters

 fda-says-baxter-issues-urgent-medical-device-recall-for-volar-system-single-patient-use-circuit-baxters-recall-is-due-to-reports-of-the-handset-plug-disconnecting-from-the-nebulizer-port-on-the-blue-ventilator-adapter

- Reuters 

 fda-says-baxter-recalls-life2000-ventilator-due-to-potential-failure-of-battery-charging-dongle-identifies-baxter-life2000-ventilator-recall-as-most-serious-type

- Reuters 

 morgan-stanley-downgrades-baxter-intl-to-underweight-lowers-price-target-to-30

Morgan Stanley analyst Patrick Wood downgrades Baxter Intl (NYSE:BAX) from Equal-Weight to Underweight and lowers the price ...

 citigroup-maintains-neutral-on-baxter-intl-lowers-price-target-to-37

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Neutral and lowers the price target from $38 to $37.

 baxter-international-issues-urgent-medical-device-recall-for-life2000-ventilator-due-to-potential-battery-charger-dongle-damage-reports-indicate-improper-charging-one-serious-injury-complaint-received-working-with-customers-to-replace-affected-devices

https://www.baxter.com/baxter-newsroom/baxter-issues-urgent-medical-device-recall-life2000-ventilator-due-potential

 carlyle-eyes-4b-acquisition-of-baxters-kidney-care-unit-vantive-report

Carlyle is negotiating to acquire Baxter International's kidney-care spinoff, Vantive, in a $4 billion deal, including debt...

Core News & Articles

Deal would value the Baxter spinoff at more than $4 billionhttps://www.wsj.com/finance/investing/carlyle-in-advanced-talks-to-a...

 evercore-isi-group-maintains-outperform-on-baxter-intl-lowers-price-target-to-45

Evercore ISI Group analyst Vijay Kumar maintains Baxter Intl (NYSE:BAX) with a Outperform and lowers the price target from $...

 goldman-sachs-initiates-coverage-on-baxter-intl-with-neutral-rating-announces-price-target-of-36

Goldman Sachs analyst David Roman initiates coverage on Baxter Intl (NYSE:BAX) with a Neutral rating and announces Price Tar...

 citigroup-maintains-neutral-on-baxter-intl-lowers-price-target-to-38

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Neutral and lowers the price target from $44 to $38.

 fresenius-ses-future-with-dialysis-company-unclear-investors-seek-answers

Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite hol...